# Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment

> **NCT02254070** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 23 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBT 986 BS

## Key facts

- **NCT ID:** NCT02254070
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2004-08
- **Final completion:** —
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254070, "Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02254070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*